Composition of matter patent secures exclusive protection for Anixa’s breast cancer vaccine in Australia through 2040, expanding the Company’s growing global IP estate
Tracking down senescent cells, which accumulate as we age, could help diagnose age-related disorders and guide researchers working on new treatments.
Scientists at the University of Galway have taken part in a first-in-human study of stroke patients using a thin wire fitted with sensors to assess and map their clots.
Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the country, led the development of a new investigational blood test that could detect pancreatic cancer at its earliest stages, when the disease is more treatable and potentially curable.
In the sickest COVID-19 patients, SARS-CoV-2 doesn’t just cause severe damage by directly infecting airway cells. The virus can also trigger hyperinflammation—a cycle in which immune cells themselves become infected, stop fighting the virus and instead trigger high levels of inflammation throughout the lungs.
Researchers at Wake Forest University School of Medicine have identified a protein that may help an aggressive form of breast cancer spread to the brain and escape the body’s immune defenses.
Researchers have uncovered a previously unknown gene that causes resistance to a leading blood cancer drug, as well as several genes that accelerate lymphoma growth, using a powerful new CRISPR activation library.
The FDA has given the go-ahead to Ultragenyx’s rebisufligene etisparvovec—now to be marketed under the brand name Fayuvi—for the treatment of Sanfilippo syndrome type A, an ulta-rare, progressive neurological condition in children.
The 62-patient multicentre trial is evaluating a nanoparticle-based platform designed to help identify sentinel lymph nodes in gastric and oesophageal cancer surgery.
There is no cure for HIV. While scientists have made considerable progress in controlling the infection, patients still must take daily antiretroviral medication for the rest of their lives. Results from a clinical trial led by Rockefeller, Imperial College London, and the University of Oxford (RIO) have offered a new strategy, suggesting that just one or two doses of broadly neutralizing antibodies (bNAbs) can suppress the virus long term, keeping it at undetectable levels for months and even years.